# Efficacy and Safety of Dapagliflozin in Acute Heart Failure

Study · id `cardio:ct-nct04298229` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04298229](<https://clinicaltrials.gov/study/NCT04298229>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04298229

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Heart failure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT04298229. Randomized; single masking; primary purpose treatment. Start 2020-04-01 (actual); primary completion 2023-05-17 (actual). Results posted on 2024-03-15.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT04298229, source copy `cardio:ctgov-nct04298229-2024-03-15`, retrieved 2026-10-26)
- Started: 2020-04-01 (actual) (ClinicalTrials.gov record NCT04298229, source copy `cardio:ctgov-nct04298229-2024-03-15`, retrieved 2026-10-26)
- Primary completion: 2023-05-17 (actual) (ClinicalTrials.gov record NCT04298229, source copy `cardio:ctgov-nct04298229-2024-03-15`, retrieved 2026-10-26)
- Completion: 2023-05-17 (actual) (ClinicalTrials.gov record NCT04298229, source copy `cardio:ctgov-nct04298229-2024-03-15`, retrieved 2026-10-26)
- Results first posted: 2024-03-15 (ClinicalTrials.gov record NCT04298229, source copy `cardio:ctgov-nct04298229-2024-03-15`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04298229, source copy `cardio:ctgov-nct04298229-2024-03-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04298229-2024-03-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Dapagliflozin in Acute Heart Failure
- Acronym: DICTATE-AHF
- Condition: Heart Failure
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Dapagliflozin 10 MG
- Intervention (Other): Protocolized Diuretic Therapy
- Lead sponsor: Vanderbilt University Medical Center
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Vanderbilt University Medical Center (`cardio:org-vanderbilt-university-medical-center`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure (`cardio:pubmed-38569758`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Interaction of Kidney Function and Dapagliflozin in Patients With Acute Heart Failure: A Pre-Specified Analysis of DICTATE-AHF (`cardio:pubmed-42013970`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 15f413446f29fc6b9364dbf0783be46aa550ca1bf504d5c2340d5fbca57fe7ae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
